Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Naveen Pemmaraju, Prithviraj Bose, Raajit Rampal, Aaron T. Gerds, Angela Fleischman & Srdan Verstovsek. (2023) Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leukemia & Lymphoma 64:6, pages 1063-1081.
Read now
Read now
Khalil Saleh & Vincent Ribrag. (2023) An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis. Expert Review of Hematology 16:4, pages 227-236.
Read now
Read now
John Mascarenhas. (2022) Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert Review of Hematology 15:8, pages 671-684.
Read now
Read now
Prithviraj Bose & Ruben A. Mesa. (2022) Novel strategies for challenging scenarios encountered in managing myelofibrosis. Leukemia & Lymphoma 63:4, pages 774-788.
Read now
Read now
Giacomo Coltro & Alessandro M. Vannucchi. (2021) The safety of JAK kinase inhibitors for the treatment of myelofibrosis. Expert Opinion on Drug Safety 20:2, pages 139-154.
Read now
Read now
Jan Philipp Bewersdorf, Sara Mohamed Jaszczur, Salma Afifi, Jennifer C Zhao & Amer M Zeidan. (2019) Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis. Cancer Management and Research 11, pages 10777-10790.
Read now
Read now
Suliman Al-Fayoumi, Taishi Hashiguchi, Yuka Shirakata, John Mascarenhas & Jack W Singer. (2018) Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis. Journal of Experimental Pharmacology 10, pages 9-17.
Read now
Read now
Douglas Tremblay & John Mascarenhas. (2018) Pacritinib to treat myelofibrosis patients with thrombocytopenia. Expert Review of Hematology 11:9, pages 707-714.
Read now
Read now
Prithviraj Bose, Abdallah Abou Zahr & Srdan Verstovsek. (2017) Investigational Janus kinase inhibitors in development for myelofibrosis. Expert Opinion on Investigational Drugs 26:6, pages 723-734.
Read now
Read now
Tania Jain & Ruben Mesa. (2016) The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. Expert Review of Anticancer Therapy 16:11, pages 1101-1108.
Read now
Read now
Articles from other publishers (53)
Ismail Sami Mahmoud, Yazun Bashir Jarrar & Febrimarsa. (2023) Modulation of IRAK enzymes as a therapeutic strategy against SARS-CoV-2 induced cytokine storm. Clinical and Experimental Medicine.
Crossref
Crossref
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka & Sabine Klein. (2023) Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis. Hepatology 77:4, pages 1228-1240.
Crossref
Crossref
Gizem Kayki-Mutlu, Zinnet Sevval Aksoyalp, Leszek Wojnowski & Martin C. Michel. (2023) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Nem Kumar Jain, Mukul Tailang, Hemant Kumar Jain, Balakumar Chandrasekaran, Biswa Mohan Sahoo, Anandhalakshmi Subramanian, Neelaveni Thangavel, Afaf Aldahish, Kumarappan Chidambaram, M. Alagusundaram, Santosh Kumar & Palani Selvam. (2023) Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review. Frontiers in Pharmacology 14.
Crossref
Crossref
Chiara Ghezzi, Bao Ying Chen, Robert Damoiseaux & Peter M. Clark. (2023) Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3. Scientific Reports 13:1.
Crossref
Crossref
骏 杨. (2023) MPN-Related Mutations and JAK2 Inhibitor Therapy. Advances in Clinical Medicine 13:01, pages 238-245.
Crossref
Crossref
Ansab Akhtar, Jaspreet Kaur, Mei Nee Chiu & Sangeeta Pilkhwal Sah. 2023. Drug Repurposing for Emerging Infectious Diseases and Cancer. Drug Repurposing for Emerging Infectious Diseases and Cancer
395
421
.
Samuel B. Reynolds & Kristen Pettit. (2022) New approaches to tackle cytopenic myelofibrosis. Hematology 2022:1, pages 235-244.
Crossref
Crossref
Massimo Breccia, Giovanni Manfredi Assanto, Alessandro Laganà, Emilia Scalzulli & Maurizio Martelli. (2022) Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors. Current Opinion in Oncology 34:6, pages 729-737.
Crossref
Crossref
Naveen Pemmaraju, Claire Harrison, Vikas Gupta, Srdan Verstovsek, Bart Scott, Stephen T. Oh, Francesca Palandri, Haifa Kathrin Al‐Ali, Marta Sobas, Mary Frances McMullin, Ruben Mesa, Sarah Buckley, Karisse Roman‐Torres, Alessandro Vannucchi & Abdulraheem Yacoub. (2022) Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis. eJHaem 3:4, pages 1346-1351.
Crossref
Crossref
Julian A. Waksal & John Mascarenhas. (2022) Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors. Current Hematologic Malignancy Reports 17:5, pages 140-154.
Crossref
Crossref
Undraga Schagdarsurengin, Vanessa Breiding, Maria Loose, Florian Wagenlehner & Temuujin Dansranjav. (2022) Interleukin-1 receptor associated kinase 1 (IRAK1) is epigenetically activated in luminal epithelial cells in prostate cancer. Frontiers in Oncology 12.
Crossref
Crossref
Sangeetha Venugopal & John Mascarenhas. (2022) The odyssey of pacritinib in myelofibrosis. Blood Advances 6:16, pages 4905-4913.
Crossref
Crossref
Charlotte EJ. Downes, Barbara J. McClure, Daniel P. McDougal, Susan L. Heatley, John B. Bruning, Daniel Thomas, David T. Yeung & Deborah L. White. (2022) JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Thomas Hoyler, Bettina Bannert, Cédric André, Damian Beck, Thomas Boulay, David Buffet, Nadja Caesar, Thomas Calzascia, Janet Dawson, Diego Kyburz, Robert Hennze, Christine Huppertz, Amanda Littlewood-Evans, Pius Loetscher, Kirsten D. Mertz, Satoru Niwa, Gautier Robert, James S. Rush, Giulia Ruzzante, Sophie Sarret, Thomas Stein, Ismahane Touil, Grazyna Wieczorek, Geraldine Zipfel, Stuart Hawtin & Tobias Junt. (2022) Nonhematopoietic IRAK1 drives arthritis via neutrophil chemoattractants. JCI Insight 7:13.
Crossref
Crossref
Grant R. Campbell, Pratima Rawat & Stephen A. Spector. (2022) Pacritinib Inhibition of IRAK1 Blocks Aberrant TLR8 Signalling by SARS-CoV-2 and HIV-1-Derived RNA. Journal of Innate Immunity, pages 1-11.
Crossref
Crossref
Dahniel Sastow, John Mascarenhas & Douglas Tremblay. (2022) Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment. Clinical Lymphoma Myeloma and Leukemia 22:7, pages e507-e520.
Crossref
Crossref
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, Ahmed H. Abdelazeem & Ahmed M. Gouda. (2022) A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics 14:5, pages 1001.
Crossref
Crossref
Yvette N. Lamb. (2022) Pacritinib: First Approval. Drugs 82:7, pages 831-838.
Crossref
Crossref
Giuseppe G. Loscocco & Alessandro M. Vannucchi. (2022) Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives. International Journal of Hematology 115:5, pages 626-644.
Crossref
Crossref
Baohuan Cai, Yun Liu, Yating Chong, Hualei Zhang, Atsuko Matsunaga, Xuexiu Fang, Rafal Pacholczyk, Gang Zhou, John K. Cowell & Tianxiang Hu. (2021) IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies. Molecular Cancer 20:1.
Crossref
Crossref
Ahmed H. Abdelazeem, Alaa M. Alqahtani, Hany H. Arab, Ahmed M. Gouda & Asmaa G. Safi El-Din. (2021) Novel benzo[4,5]thiazolo[2,3-C][1,2,4]triazoles: Design, synthesis, anticancer evaluation, kinase profiling and molecular docking study. Journal of Molecular Structure 1246, pages 131138.
Crossref
Crossref
Paul Beinhoff, Lavannya Sabharwal, Vindhya Udhane, Cristina Maranto, Peter S. LaViolette, Kenneth M. Jacobsohn, Susan Tsai, Kenneth A. Iczkowski, Liang Wang, William A. Hall, Scott M. Dehm, Deepak Kilari & Marja T. Nevalainen. (2021) Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?. Cancers 13:20, pages 5204.
Crossref
Crossref
Prithviraj Bose & Srdan Verstovsek. (2021) SOHO State of the Art Updates and Next Questions: Identifying and Treating “Progression” in Myelofibrosis. Clinical Lymphoma Myeloma and Leukemia 21:10, pages 641-649.
Crossref
Crossref
Srdan Verstovsek, Ruben Mesa, Moshe Talpaz, Jean-Jacques Kiladjian, Claire N. Harrison, Stephen T. Oh, Alessandro M. Vannucchi, Raajit Rampal, Bart L. Scott, Sarah A. Buckley, Adam R. Craig, Karisse Roman-Torres & John O. Mascarenhas. (2021) Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica 107:7, pages 1599-1607.
Crossref
Crossref
Bernhard Moser, Sophie Edtmayer, Agnieszka Witalisz-Siepracka & Dagmar Stoiber. (2021) The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia. Biomedicines 9:8, pages 1051.
Crossref
Crossref
Christoph Rummelt, Sivahari P. Gorantla, Manja Meggendorfer, Anne Charlet, Cornelia Endres, Konstanze Döhner, Florian H. Heidel, Thomas Fischer, Torsten Haferlach, Justus Duyster & Nikolas von Bubnoff. (2020) Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. Leukemia 35:7, pages 2017-2029.
Crossref
Crossref
Klara Klein, Dagmar Stoiber, Veronika Sexl & Agnieszka Witalisz-Siepracka. (2021) Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?. Cancers 13:11, pages 2611.
Crossref
Crossref
Torsten Steinbrunn, Josip Zovko & Sabrina Kraus. (2021) JAK-Inhibitoren für die Behandlung hämatoonkologischer Erkrankungen. TumorDiagnostik & Therapie 42:03, pages 176-184.
Crossref
Crossref
Sime Brkic & Sara C. Meyer. (2021) Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. HemaSphere 5:1, pages e516.
Crossref
Crossref
Torsten Steinbrunn, Josip Zovko & Sabrina Kraus. (2020) JAK-Inhibitoren für die Behandlung hämatoonkologischer Erkrankungen. Aktuelle Rheumatologie 45:06, pages 559-567.
Crossref
Crossref
Ahmed H. Abdelazeem, Alaa M. Alqahtani, Hany A. Omar, Syed Nasir Abbas Bukhari & Ahmed M. Gouda. (2020) Synthesis, biological evaluation and kinase profiling of novel S-benzo[4,5]thiazolo[2,3-c][1,2,4]triazole derivatives as cytotoxic agents with apoptosis-inducing activity. Journal of Molecular Structure 1219, pages 128567.
Crossref
Crossref
Joanna Zabkiewicz, Michelle Lazenby, Gareth Edwards, Ceri A. Bygrave, Nader Omidvar, Lihui Zhuang, Steve Knapper, Carol Guy, Robert K. Hills, Alan K. Burnett & Caroline L. Alvares. (2020)
Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of
FLT3
‐ITD acute myeloid leukaemia
. British Journal of Haematology 191:2, pages 231-242.
Crossref
Crossref
Paul A. Wadsworth, Aditya K. Singh, Nghi Nguyen, Nolan M. Dvorak, Cynthia M. Tapia, William K. Russell, Clifford Stephan & Fernanda Laezza. (2020) JAK2 regulates Nav1.6 channel function via FGF14Y158 phosphorylation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1867:10, pages 118786.
Crossref
Crossref
Julian Grabek, Jasmin Straube, Megan Bywater & Steven W. Lane. (2020) MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment. Cells 9:8, pages 1901.
Crossref
Crossref
Gerhard Rogler. (2020) Efficacy of JAK inhibitors in Crohn’s Disease. Journal of Crohn's and Colitis 14:Supplement_2, pages S746-S754.
Crossref
Crossref
Alessandra Iurlo, Daniele Cattaneo & Cristina Bucelli. (2020) Management of Myelofibrosis: from Diagnosis to New Target Therapies. Current Treatment Options in Oncology 21:6.
Crossref
Crossref
Ping Xin, Xiaoyun Xu, Chengjie Deng, Shuang Liu, Youzhi Wang, Xuegang Zhou, Hongxing Ma, Donghua Wei & Shiqin Sun. (2020) The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology 80, pages 106210.
Crossref
Crossref
Sangeetha Venugopal, Michal Bar-Natan & John O. Mascarenhas. (2020) JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia. Blood Reviews 40, pages 100634.
Crossref
Crossref
Katharine V Jensen, Xiaoguang Hao, Ahmed Aman, H Artee Luchman & Samuel Weiss. (2020) EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo. Neuro-Oncology Advances 2:1.
Crossref
Crossref
Peter H. Liu & Samuel Sidi. (2019) Targeting the Innate Immune Kinase IRAK1 in Radioresistant Cancer: Double-Edged Sword or One-Two Punch?. Frontiers in Oncology 9.
Crossref
Crossref
Jack W. Singer, Suliman Al-Fayoumi, Jason Taylor, Sharlene Velichko & Alison O’Mahony. (2019) Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. PLOS ONE 14:9, pages e0222944.
Crossref
Crossref
Lucia Masarova, Prithviraj Bose & Srdan Verstovsek. (2019) The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports 14:4, pages 310-327.
Crossref
Crossref
Prithviraj Bose, Mansour Alfayez & Srdan Verstovsek. (2019) New Concepts of Treatment for Patients with Myelofibrosis. Current Treatment Options in Oncology 20:1.
Crossref
Crossref
Mona M. Hosseini, Stephen E. Kurtz, Sherif Abdelhamed, Shawn Mahmood, Monika A. Davare, Andy Kaempf, Johannes Elferich, Jason E. McDermott, Tao Liu, Samuel H. Payne, Ujwal Shinde, Karin D. Rodland, Motomi Mori, Brian J. Druker, Jack W. Singer & Anupriya Agarwal. (2018) Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia 32:11, pages 2374-2387.
Crossref
Crossref
Yu-yi Chu-Farseeva, Nurulhuda Mustafa, Anders Poulsen, Eng Chong Tan, Jeffrey J.Y. Yen, Wee Joo Chng & Brian W. Dymock. (2018) Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. European Journal of Medicinal Chemistry 158, pages 593-619.
Crossref
Crossref
Jack W. Singer, Angela Fleischman, Suliman Al-Fayoumi, John O. Mascarenhas, Qiang Yu & Anupriya Agarwal. (2018) Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget 9:70, pages 33416-33439.
Crossref
Crossref
Adolfo Enrique Diaz & Ruben A Mesa. (2018) Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. Future Oncology 14:9, pages 797-807.
Crossref
Crossref
Brian C. BettsDavid BastianSupinya IamsawatHung Nguyen, Jessica L. HeinrichsYongxia WuAnusara DaenthanasanmakAnandharaman VeerapathranAlison O’MahonyKelly WaltonJordan ReffPedro HornaElizabeth M. SagatysMarie C. LeeJack SingerYing-Jun ChangChen Liu, Joseph PidalaClaudio AnasettiXue-Zhong Yu. (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proceedings of the National Academy of Sciences 115:7, pages 1582-1587.
Crossref
Crossref
Leonard Naymagon & John Mascarenhas. (2017) Myelofibrosis-Related Anemia. HemaSphere 1:1, pages e1.
Crossref
Crossref
Jian Yuan Goh, Min Feng, Wenyu Wang, Gokce Oguz, Siti Maryam J M Yatim, Puay Leng Lee, Yi Bao, Tse Hui Lim, Panpan Wang, Wai Leong Tam, Annette R Kodahl, Maria B Lyng, Suman Sarma, Selena Y Lin, Alexander Lezhava, Yoon Sim Yap, Alvin S T Lim, Dave S B Hoon, Henrik J Ditzel, Soo Chin Lee, Ern Yu Tan & Qiang Yu. (2017) Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nature Medicine 23:11, pages 1319-1330.
Crossref
Crossref
Akihide YoshimiMaria E. BalasisAlexis VedderKira FeldmanYan MaHailing ZhangStanley Chun-Wei LeeChristopher LetsonSandrine NiyongereSydney X. LuMarkus BallJustin TaylorQing ZhangYulong ZhaoSalma YoussefYoung Rock ChungXiao Jing ZhangBenjamin H. DurhamWendy Yang, Alan F. ListMignon L. LohVirginia Klimek, Michael F. Berger, Elliot StieglitzEric PadronOmar Abdel-Wahab. (2017) Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood 130:4, pages 397-407.
Crossref
Crossref
Ruben A Mesa, Alessandro M Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Janos Jakucs, Andrew Perkins, Ritam Prasad, Jiri Mayer, Judit Demeter, Peter Ganly, Jack W Singer, Huafeng Zhou, James P Dean, Peter A te Boekhorst, Jyoti Nangalia, Jean-Jacques Kiladjian & Claire N Harrison. (2017) Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. The Lancet Haematology 4:5, pages e225-e236.
Crossref
Crossref